154 related articles for article (PubMed ID: 8329833)
1. Effects of luteinizing hormone-releasing hormone agonists on final height in luteinizing hormone-releasing hormone-dependent precocious puberty.
Oerter KE; Manasco PK; Barnes KM; Jones J; Hill S; Cutler GB
Acta Paediatr Suppl; 1993 Mar; 388():62-8; discussion 69. PubMed ID: 8329833
[No Abstract] [Full Text] [Related]
2. Final height in girls with central precocious puberty: comparison of two different luteinizing hormone-releasing hormone agonist treatments.
Antoniazzi F; Cisternino M; Nizzoli G; Bozzola M; Corrias A; De Luca F; De Sanctis C; Rigon F; Zamboni G; Bernasconi S
Acta Paediatr; 1994 Oct; 83(10):1052-6. PubMed ID: 7841703
[TBL] [Abstract][Full Text] [Related]
3. [Comparison between complete and incomplete suppression of the hypophyseal-gonadal axis in girls with central precocious puberty: effect on growth and prospective final height].
Partsch CJ; Hümmelink R; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Monatsschr Kinderheilkd; 1993 Dec; 141(12):935-9. PubMed ID: 8114776
[TBL] [Abstract][Full Text] [Related]
4. Comparison of complete and incomplete suppression of pituitary-gonadal activity in girls with central precocious puberty: influence on growth and predicted final height. The German-Dutch Precocious Puberty Study Group.
Partsch CJ; Hümmelink R; Peter M; Sippell WG; Oostdijk W; Odink RJ; Drop SL
Horm Res; 1993; 39(3-4):111-7. PubMed ID: 8262471
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone analogues in the management of precocious puberty.
Spiliotis BE
Ann N Y Acad Sci; 2000; 900():429-34. PubMed ID: 10818433
[No Abstract] [Full Text] [Related]
6. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues.
Bertelloni S; Baroncelli GI; Ferdeghini M; Menchini-Fabris F; Saggese G
Eur J Pediatr; 2000 May; 159(5):369-74. PubMed ID: 10834524
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of post-menarche idiopathic central precocious puberty in girls with combined gonadotropin-releasing hormone analog and growth hormone].
Li Y; Liang L; Sun LY; Dong GP
Zhonghua Er Ke Za Zhi; 2005 Aug; 43(8):627-8. PubMed ID: 16191282
[No Abstract] [Full Text] [Related]
8. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.
Bertelloni S; Baroncelli GI; Sorrentino MC; Perri G; Saggese G
Eur J Pediatr; 1998 May; 157(5):363-7. PubMed ID: 9625331
[TBL] [Abstract][Full Text] [Related]
9. Variations in pituitary-gonadal suppression during intranasal buserelin and intramuscular depot-triptorelin therapy for central precocious puberty. Belgian Study Group for Pediatric Endocrinology.
Heinrichs C; Craen M; Vanderschueren-Lodeweyckx M; Malvaux P; Fawe L; Bourguignon JP
Acta Paediatr; 1994 Jun; 83(6):627-33. PubMed ID: 7919761
[TBL] [Abstract][Full Text] [Related]
10. Six-year results of luteinizing hormone releasing hormone (LHRH) agonist treatment in children with LHRH-dependent precocious puberty.
Manasco PK; Pescovitz OH; Hill SC; Jones JM; Barnes KM; Hench KD; Loriaux DL; Cutler GB
J Pediatr; 1989 Jul; 115(1):105-8. PubMed ID: 2661787
[No Abstract] [Full Text] [Related]
11. Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone.
Cara JF; Kreiter ML; Rosenfield RL
J Pediatr; 1992 May; 120(5):709-15. PubMed ID: 1533661
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors for the effect of gonadotrophin releasing hormone analogue therapy on the height of girls with idiopathic central precocious puberty.
Brauner R; Malandry F; Rappaport R
Eur J Pediatr; 1992 Oct; 151(10):728-30. PubMed ID: 1425790
[TBL] [Abstract][Full Text] [Related]
13. [Undulating course of precocious puberty].
Kolmer M; Schulz U; Herkner K; Frisch H; Waldhauser F
Padiatr Padol; 1991; 26(6):271-4. PubMed ID: 1838804
[TBL] [Abstract][Full Text] [Related]
14. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
[TBL] [Abstract][Full Text] [Related]
15. Time to menarche and final height after histrelin implant treatment for central precocious puberty.
Gillis D; Karavani G; Hirsch HJ; Strich D
J Pediatr; 2013 Aug; 163(2):532-6. PubMed ID: 23485026
[TBL] [Abstract][Full Text] [Related]
16. End results in central precocious puberty with GnRH analog treatment: the data of the Italian Study Group for Physiopathology of Puberty.
Antoniazzi F; Arrigo T; Cisternino M; Galluzzi F; Bertelloni S; Pasquino AM; Borrelli P; Osio D; Mengarda F; De Luca F; Tatò L
J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():773-80. PubMed ID: 10969920
[TBL] [Abstract][Full Text] [Related]
17. Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
Pasquino AM; Pucarelli I; Accardo F; Demiraj V; Segni M; Di Nardo R
J Clin Endocrinol Metab; 2008 Jan; 93(1):190-5. PubMed ID: 17940112
[TBL] [Abstract][Full Text] [Related]
18. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.
Oostdijk W; Drop SL; Odink RJ; Hümmelink R; Partsch CJ; Sippell WG
Acta Paediatr Scand Suppl; 1991; 372():39-45; discussion 46. PubMed ID: 1833950
[TBL] [Abstract][Full Text] [Related]
19. GH and GnRH analog treatment in children who enter puberty at short stature.
Tanaka T; Satoh M; Yasunaga T; Horikawa R; Tanae A; Hibi I
J Pediatr Endocrinol Metab; 1997; 10(6):623-8. PubMed ID: 9467133
[TBL] [Abstract][Full Text] [Related]
20. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
Lanes R; Soros A; Jakubowicz S
J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
